Current Medical Research and Opinion, Journal Year: 2024, Volume and Issue: 40(10), P. 1793 - 1808
Published: Aug. 23, 2024
Depression is a serious psychiatric disorder with high incidence of morbidity and mortality psilocybin psychotherapy has emerged as promising potential in the treatment depressive disorders. A review use patients disorders presented.A search was conducted investigating resistant depression
Language: Английский
Brain Sciences, Journal Year: 2023, Volume and Issue: 13(10), P. 1494 - 1494
Published: Oct. 22, 2023
The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ patients' perceptions about helpfulness treatments. We aimed to verify effect ESK-NS view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with (mean dose: 78.4 11.43 mg) three months and evaluated at different time-points through self-administered scales, assessing changes depression, anhedonia, sleep, cognition, suicidality, anxiety. observed an overall early improvement that lasted over time (endpoint total score reduction Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Inventory, = 0.003). Patients reported a significant self-rated decrease anhedonia two (Snaith-Hamilton Pleasure 0.04) suicide ideation endpoint (BDI subitem 9, 0.039) vs. earlier improvements detected clinicians (one-month MADRS 8, 0.005, 10, 0.007). These findings confirm three-month treatment patients, highlighting overlapping response clinicians' perspectives, although some differential effects on specific symptoms given time-points. Including viewpoints routine could inform clinical practice, ensuring better characterization phenotypes deliver personalized interventions.
Language: Английский
Citations
10
Disease-a-Month, Journal Year: 2024, Volume and Issue: 70(9), P. 101725 - 101725
Published: March 12, 2024
Language: Английский
Citations
3
International Clinical Psychopharmacology, Journal Year: 2024, Volume and Issue: 40(2), P. 53 - 61
Published: Jan. 26, 2024
Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was systematically review the literature about depressive disorders. A bibliographic search conducted in main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted articles written English language effectiveness symptoms. Most included studies randomized controlled trials (10 out 12). available agrees indicating is effective improving symptoms especially when compared inactivity practice administered a medium-long period (8-16 weeks). In addition, seems at least comparable than aerobic exercise. can be considered reliable complementary treatment people with These findings should interpreted considering different types as well duration programs or rating scales used assess mood Studies more homogenous design needed confirm make generalizable results presented review.
Language: Английский
Citations
2
Clinical Psychopharmacology and Neuroscience, Journal Year: 2024, Volume and Issue: 22(2), P. 201 - 210
Published: Feb. 15, 2024
For the first time after many decades, new antidepressants have been approved and more are under various stages of development will soon be available in market. The drugs present a range mechanisms action with benefits terms speed action, tolerability treatable disorders. Neurosteroids recently their rapid benefit may extend from postpartum depression to anxious bipolar depression, dextromethorphan bupropion combination prove useful major but also treatment resistant dextromethadone is possible augmentation partial antidepressant response, psychedelic potential long lasting single administration, though still experimental treatments. Botulinum has same advantage psychedelics administration its effects last for weeks or more. Further potentially interesting include drug targets, repurposing genetic epigenetic manipulations. It therefore important that clinicians kept up date evidence so can rapidly translated into clinical practice.
Language: Английский
Citations
2
Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18
Published: April 25, 2024
Background Current treatment modalities for Major Depressive Disorder have variable efficacies and a variety of side effects. To amend this, many trials short term, well tolerated monotherapies are underway. One such option is Zuranolone (SAGE-217), which recent FDA approved antidepressant Post Partum depression (PPD) undergoing clinical PPD, major depressive disorder (MDD) essential tremors (ET). Objectives Pool currently available data that compare to Placebo the evaluate its efficacy safety profile. Methods We retrieved from PUBMED SCOPUS inception July 2023. included articles comparing or SAGE 217 with placebo in patients suffering Disorder. Review Manager 5.4 was used analyze outcomes including changes Hamilton Depression Rating Scale (HAM-D), Anxiety (HAM-A) Montgomery–Åsberg (MADRS) scores baseline as any emergent adverse events (TEAEs) severe events. Results Our review analyzed 4 1,357 patients. Patients treated indicated statistically significant effect change HAM-D score ( p = 0.0009; MD [95% CI]: −2.03 [−3.23, −0.84]) MADRS 0.02; −2.30[−4.31, −0.30]) HAM-A 0.03; −1.41[−2.70, −0.11]) on 15th day when compared group. also significantly associated higher response rate 0.0008; OR 1.63[1.14, 2.35]) remission 1.65[1.05, 2.59]) placebo. As safety, 1 more TEAE 0.006; RR 1.14[1.04, 1.24]) but an insignificant association effects lead drug discontinuation 0.70; 1.18[0.51, 2.76]) serious 0.48; 1.46 [0.52, 4.10]) Conclusion effective safe course monotherapy. It shows results 14 days (compared 2–4 weeks SSRI’s take) has anti-anxiolytic well. However, only been analysis sample size small. The reviewed cannot determine long-term drug. More needed long term
Language: Английский
Citations
2
Advances in experimental medicine and biology, Journal Year: 2024, Volume and Issue: unknown, P. 49 - 66
Published: Jan. 1, 2024
Language: Английский
Citations
2
Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
2
CNS Spectrums, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 15
Published: Dec. 10, 2024
Abstract The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin’s efficacy, juxtaposing benefits with practical aspects psychedelic-assisted psychotherapy (PAP) methodological constraints existing research. An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored clinical use obsessive-compulsive disorder, post-traumatic stress substance disorder. Despite promising preliminary results suggesting efficacy alleviating depression anxiety, as well obsessions, compulsions, addictive behaviors, significant gaps persist. These include evaluating compared standard antidepressants or anxiolytic molecules identifying patient subpopulations might benefit most from PAP. Concerns about safety, long-term optimal dosage remain unclear due previous trials’ limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, unresolved legal ethical issues. paper argues further substantiate base, emphasizing need larger overcome limitations explore full therapeutic potential. While holds promise psychiatry, its successful translation practice demands more robust rigor. In addition, factors, such cultural stigma legal/ethical issues, be successfully addressed facilitate healthcare systems.
Language: Английский
Citations
2
International Clinical Psychopharmacology, Journal Year: 2024, Volume and Issue: unknown
Published: June 17, 2024
Postpartum depression (PPD) is an increasingly prevalent but still poorly characterized disorder. Causal and modulating factors include hormones fluctuations, such as estrogen, progesterone, allopregnolone, pathways imbalances, oxytocin kynurenine, chronobiological factors, brain imaging alterations. Treatment may differ from the traditional major management, while selective serotonin reuptake inhibitors sertraline are commonly used suggested by guidelines, neurosteroids brexanolone more convenient zuranolone have been recently approved. Newer ganaxolone, valaxanolone, lysaxanolone currently under development, also esketamine psychedelics promising potential treatments. Other somatic treatments including stimulation techniques light therapy showed benefit. PPD therefore understood as, at least partially, independent depressive Specific individualized pharmacological non-pharmacological therapies progressively being introduced in routine clinical practice.
Language: Английский
Citations
1
Indian Journal of Psychological Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: July 31, 2024
Background: Cognitive dysfunctions play a critical role in the psychopathology of depression. They regulate various psychosocial and functional outcomes affect workplace functionality, productivity, relapses. An objective evaluation affected cognitive domains is germane understanding relapses recovery Thus, to know beyond affective biases, this study was conducted compare functions drug-naïve patients with unipolar depression healthy matched controls. Methods: Fifty diagnosed as per International Classification Diseases, tenth revision: Diagnostic Criteria for Research (Depressive Episode Recurrent Depressive Disorder) 50 controls were enrolled on an outpatient basis from January 2022 June 2023. Cases regrouped mild, moderate, severe based Beck’s Depression Inventory (BDI-II). A battery tests assessed functions: Wisconsin Card Sorting Test, Trail Making Visual Retention subtests PGI Battery Brain Dysfunction, Digit Span, Verbal Memory. The Massachusetts General Hospital Physical Functioning Questionnaire used subjective assessment functioning. Results: sociodemographic characteristics cases did not differ significantly. However, within-group between-group analyses revealed significantly lower performance compared impairment positively correlated BDI-II scores. Conclusion: associated dysfunction planning, attention, sustained visual verbal memory. This independent bias may exist even after clinical remission.
Language: Английский
Citations
1